Targeting of erbB3 receptor to overcome resistance in cancer treatment by Jian Ma et al.
Ma et al. Molecular Cancer 2014, 13:105
http://www.molecular-cancer.com/content/13/1/105REVIEW Open AccessTargeting of erbB3 receptor to overcome
resistance in cancer treatment
Jian Ma1,2, Hui Lyu1, Jingcao Huang1 and Bolin Liu1*Abstract
The erbB receptors, including the epidermal growth factor receptor (EGFR), erbB2 (also known as HER2/neu), erbB3
(or HER3), and erbB4 (or HER4), are often aberrantly activated in a wide variety of human cancers. They are excellent
targets for selective anti-cancer therapies because of their transmembrane location and pro-oncogenic activity. While
several therapeutic agents against erbB2 and/or EGFR have been used in the treatment of human cancers with efficacy,
there has been relatively less emphasis on erbB3 as a molecular target. Elevated expression of erbB3 is frequently
observed in various malignancies, where it promotes tumor progression via interactions with other receptor tyrosine
kinases (RTKs) due to its lack of or weak intrinsic kinase activity. Studies on the underlying mechanisms implicate erbB3
as a major cause of treatment failure in cancer therapy, mainly through activation of the PI-3 K/Akt, MEK/MAPK, and
Jak/Stat signaling pathways as well as Src kinase. It is believed that inhibition of erbB3 signaling may be required to
overcome therapeutic resistance and effectively treat cancers. To date, no erbB3-targeted therapy has been
approved for cancer treatment. Targeting of erbB3 receptor with a monoclonal antibody (Ab) is the only strategy
currently under preclinical study and clinical evaluation. In this review, we focus on the role of erbB3-initiated
signaling in the development of cancer drug resistance and discuss the latest advances in identifying therapeutic
strategies inactivating erbB3 to overcome the resistance and enhance efficacy of cancer therapeutics.
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ErbB3 (HER3) belongs to the erbB (HER) receptor family
of type I receptor tyrosine kinases (RTKs). The erbB recep-
tor family consists of the epidermal growth factor receptor
(EGFR), erbB2 (HER2/neu), erbB3 (HER3), and erbB4
(HER4). It is arguably one of the most important receptor
families in the context of development and tumorigenesis
[1,2]. Abnormal expression and/or aberrant activation of
the erbB receptors have been demonstrated in a wide var-
iety of human cancers [3]. Dimerization of erbB receptors
is an essential step for their function and activation of the
downstream signaling pathways [3,4]. ErbB receptors nor-
mally exist as inactive monomers, with molecular folding to
prevent dimerization, with the exception of erbB2 [5,6]. As
a consequence of erbB receptor dimerization, the intracel-
lular tyrosine kinase activity is activated and the tyrosine
residues on the C-terminal tails are phosphorylated. This* Correspondence: bolin.liu@ucdenver.edu
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unless otherwise stated.subsequently leads to the recruitment of adaptor proteins
and activation of downstream signaling pathways. These in-
duce diverse biologic responses, including cell proliferation,
maturation, survival, apoptosis, and angiogenesis [3,7].
There are unique features of erbB2 and erbB3 receptors as
compared to other family members. The binding of erbB3
ligand (heregulin, HRG) exposes a dimerization arm in
the extracellular domain of erbB3 and promotes receptor-
receptor interactions [8]. ErbB3 has been considered as a
“kinase-dead” receptor [9,10], because it lacks significant in-
trinsic kinase activity [11]. Thus, in order for erbB3 to in-
duce cell signaling, it must be phosphorylated by its
interactive partners, of these, erbB2 is the most important
one [12]. In contrast, the erbB2 receptor has tyrosine kinase
activity, but it has no known ligand. ErbB2 exists in a consti-
tutively active conformation with an exposed dimerization
arm [5], that makes it as the preferred dimerization partner
for other erbB receptors [13].
ErbB3 is frequently co-expressed with other RTKs in
cancer cells. It promotes tumor initiation and progression
mainly through activation of the oncogenic PI-3 K/Akt. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Ma et al. Molecular Cancer 2014, 13:105 Page 2 of 9
http://www.molecular-cancer.com/content/13/1/105signaling. The erbB3/PI-3 K/Akt pathway is a major
cause of treatment failure in cancer therapy because of
its role in therapeutic resistance [14]. It also plays an
important role in the development of various human can-
cers, including erbB2-overexpressing (erbB2+) breast can-
cer [15,16], castration-resistant prostate cancer (CRPC)
[17], platinum-resistant/refractory ovarian cancer [18,19],
and EGFR tyrosine kinase inhibitor (TKI)-resistant non-
small cell lung cancer (NSCLC) [20,21]. For these cancers
in particular, erbB3 inhibition may be required to effect-
ively eradicate cancerous cells. Targeting of erbB3 with a
blocking antibody (Ab) is the only strategy currently being
investigated in preclinical [22,23] and clinical studies
(http://www.clinicaltrials.gov), because it lacks appreciable
kinase activity [10,11]. Several anti-erbB3 monoclonal Abs
that prevent ligand-induced activation of erbB3, such
as MM-121 and MM-111 (Merrimack Pharmaceuticals,
Cambridge, MA) and U3-1287/AMG 888 (Amgen Inc.,
Thousand Oaks, CA) have shown significant antitumor
activity in vitro and in vivo [22-25]. This review summa-
rizes the latest advances in our understanding of the
role of erbB3 signaling in cancer development and dis-
cusses novel strategies inactivating erbB3 to enhance
the efficacy of cancer therapeutics.
Characteristics of erbB3 receptor and its role in
tumorigenesis
ErbB3 receptors are not capable of forming homo-dimers,
but can induce activation of multiple downstream signaling
pathways, such as PI-3 K/Akt, MEK/MAPK, PLCγ/PKC,
Jak/Stat, and Src kinase, via hetero-dimerization with an-
other RTK [10,26]. Studies of comparing sequences of all
the erbB receptors reveal that the tyrosine kinase domain
of erbB3 diminishes several key residues, which may ex-
plain the lack of, or much lower, intrinsic kinase activity in
erbB3 [10,11]. However, once its ligand, heregulin (HRG)
(also called neuregulin (NRG)) binds to erbB3, it can recruit
another erbB receptor to form hetero-dimers, which leads
to activation of the erbB3 receptor. ErbB3 is a more potent
partner than other family members for the oncogenic activ-
ity of erbB2 [16,27-29]. It has been reported that erbB3
functions primarily to drive erbB2-mediated cell signaling
[16,30]. Our recent studies using both mouse and human
mammary/breast cancer cell models indicate that the exist-
ence of erbB3 is required to maintain erbB2’s tyrosine kin-
ase activity [31,32].
Amplification and/or overexpression of erbB3 are fre-
quently observed in various malignancies, such as cancers
of breast, gastric, ovarian, prostate, and bladder, colorectal
carcinoma, squamous cell carcinoma of the head and neck,
and melanoma [16,33,34]. A recent report identified som-
atic mutations of erbB3 occurring in approximately 11% of
colon and gastric cancers [35]. Similar to wild type erbB3,
the oncogenic activity of mutant erbB3 also depends uponthe kinase-active erbB2. The erbB3 mutants transform co-
lonic and breast epithelial cells in a ligand-independent
manner [35]. In breast cancer, both mRNA expression and
protein levels of erbB3 are upregulated. Most metastatic
breast cancers show expression of either EGFR or erbB2,
whereas upregulation of both is not typical [36]. In contrast,
co-expression of erbB2 and erbB3 is a common event in
breast cancers [37] and breast cancer-derived cell lines [38].
We and others have reported that overexpression of en-
dogenous mouse erbB3, and its association with the trans-
gene encoded erbB2, promotes mammary tumorigenesis in
the erbB2/neu-transgenic mice [39,40]. ErbB3 serves as a
critical co-receptor of erbB2, and its expression is a rate-
limiting factor for erbB2-induced breast cancer cell survival
and proliferation [15,16]. In erbB2+ breast cancer tissues,
preferential phosphorylation of erbB3, but not EGFR, has
been observed [16]. ErbB3 might also be the preferred
dimerization partner for EGFR in melanoma and pancreatic
cancer [41,42].
Elevated expression of erbB3 protein has been reported
in 50-70% of human breast cancers [43-45], and it seems
to be associated with tumor size, metastasis, and recur-
rence [46,47]. However, the prognostic value of erbB3 ex-
pression in breast cancer has been controversial [45-48].
Some studies show that erbB3 expression significantly re-
duces the overall survival and disease-free survival of
breast cancer patients [37,49,50]. Others report a positive
prognostic significance for erbB3 expression [48,51,52]. A
number of hypotheses have been proposed to explain the
dichotomous findings. They include: 1) a naturally occur-
ring secreted isoform of erbB3 (p85-soluble erbB3) which
can bind to the ligand HRG with high affinity, thereby
blocks HRG binding to the full length erbB3 on cell sur-
face and inhibits erbB3 activation [53]. This observation
could be associated with the positive prognostic value of
erbB3 in some studies. 2) subcellular distribution of erbB3
receptors may influence their biological activity. While
erbB3 pool is mainly within the intracellular compart-
ments, it seems that the levels of phosphorylated erbB3
(P-erbB3) and its activity are associated with erbB3 re-
localization to the plasma membrane [54]. 3) The ligands
such as HRGs may affect the distribution of erbB3 and in-
crease the membrane levels of the receptor [54]. Thus,
when we evaluate the impact of erbB3 on clinical outcome
of breast cancer patients, it would be better to consider
not only its expression and interactions with other
RTKs like erbB2, but also its subcellular distribution as
well as the expression levels of HRG. Nonetheless, over-
expression of erbB3 has been generally considered as a
poor prognostic factor in breast cancer patients [55].
This has been strongly supported by a recent study [56]
showing that expression of erbB3 is associated with
worse survival in a variety of human cancers of breast,
colorectal, gastric, melanoma, ovarian, head and neck,
Ma et al. Molecular Cancer 2014, 13:105 Page 3 of 9
http://www.molecular-cancer.com/content/13/1/105pancreatic, and cervical; and the influence of erbB3 may
be greater in the tumors with erbB2 overexpression.
These data further emphasize the critical role of erbB2/
erbB3 hetero-dimerization in cancer development.
ErbB3 signaling in treatment resistance of cancer
Of the four erbB receptors, erbB3 is best suited to activate
the PI-3 K/Akt signaling, because it has the most tyrosine
residues on its C-terminal tail once being phosphorated,
they are capable of binding to the p85 subunit of PI-3 K
[12,57]. In fact, among all the erbB dimerization com-
plexes, the erbB2/erbB3 hetero-dimer is the most biologic-
ally active and potent for activation of the PI-3 K/Akt
signaling cascade [58,59]. Since PI-3 K/Akt signaling is the
most important survival pathway in cell proliferation and
its activation often leads to multidrug resistance in human
cancers [60], it is understandable that one of the major
biologic consequences of erbB3 activation is to cause
treatment failure in cancer therapy [14].
Activation of erbB family members has been linked to
tamoxifen resistance of estrogen receptor (ER) positive
(ER+) breast cancers [61,62]. Cross-talk between ER and
erbB2 or EGFR signaling promotes hormone-independent
growth of breast cancer cells [63-65]. The importance of
erbB3 in the development of a tamoxifen-resistant pheno-
type is emerging. A retrospective clinical study examining
a large cohort of tamoxifen treated, ER + breast cancer pa-
tients found that the patients with co-expression of erbB2
and erbB3 were significantly more likely to relapse on
tamoxifen [66]. Another study has shown that tamoxifen-
sensitive MCF-7 cells transfected with a HRGß-2 cDNA
become estrogen-independent and resistant to tamoxifen
both in vitro and in vivo [65]. In prostate cancer, it is
known that the erbB3/PI-3 K/Akt signaling plays a critical
role in the development of castration-resistant prostate
cancer (CRPC). While androgen withdrawal therapy
(AWT) is an effective therapeutic intervention for recur-
rent prostate cancer, most patients ultimately develop re-
sistance and progress to metastatic CRPC (mCRPC) [67].
It has been reported that elevated expression of erbB3 in
CRPC leads to androgen receptor (AR) stabilization and
activation of the PI-3 K/Akt signaling [17]. Thus, erbB3
receptor may serve as a useful biomarker for modulating
tamoxifen sensitivity in luminal B (ER+, erbB2+) breast
cancer and AWT in CRPC.
The EGFR- and/or erbB2-targeted therapies approved by
FDA can be divided into two groups: 1) the blocking Abs,
such as cetuximab (Erbitux) and panitumumab (Vectibix)
against EGFR and trastuzumab (Herceptin), Pertuzumab
(Perjeta), and T-DM1 (Kadcyla) against erbB2; 2) the small
molecule tyrosine kinase inhibitors (TKIs), such as gefitinib
(Iressa) and erlotinib (Tarceva) targeting EGFR and lapati-
nib (Tykerb/Tyverb) dual-targeting both EGFR and erbB2.
All of these have been successfully used to treat a variety ofhuman cancers. The majority of cancers develop resistance
to these therapeutic Abs and/or inhibitors within one year.
Numerous studies indicate that activation of erbB3 signaling
is one of the major mechanisms of this resistance [68,69].
For example, a subset of colorectal cancer patients who ex-
hibit either de novo or acquired resistance to cetuximab-
based therapy has erbB2 amplification or high levels of
circulating HRG, which induces activation of erbB3 signal-
ing [70]. The erbB3 signaling also contributes to gefitinib re-
sistance in lung cancer-induced by gene amplification of
MET [20]. A recent study showing that dual-targeting of
EGFR and erbB3 is able to overcome acquired resistance to
cetuximab and erlotinib further confirms the importance of
erbB3 in the development of resistance to EGFR-targeted
therapy [21]. In addition, transcriptional upregulation of
erbB3 has been shown to involve in resistance to RAF/
MEK inhibitors in the treatment of melanoma and thyroid
carcinomas [71,72]. It appears that different tumors utilize
distinct mechanisms to upregulate erbB3. The RAF inhibi-
tor PLX4720 in melanoma enhanced erbB3 expression
through the transcription factor, FOXD3 [71], whereas inhib-
ition of RAF in thyroid cancers with vemurafenib (PLX4032)
induced erbB3 transcription via decreased promoter occu-
pancy by the transcriptional repressors C-terminal binding
protein 1 and 2 (CtBP1/2) [72]. Interestingly, the increased
erbB3 in melanoma or thyroid cancers also depended upon
erbB2 to activate the downstream signaling Akt [71] or
MAPK [72]. Thus, in both studies, targeting of erbB2 with
lapatinib was able to overcome the resistant phenotypes
[71,72]. In light of the importance of enhanced erbB3 expres-
sion, we hypothesize that a novel strategy to inhibit erbB3
signaling or reduce erbB3 protein levels may exhibit an even
better efficacy in combination with the RAF inhibitors.
Activation of the survival signaling - PI-3 K/Akt path-
way by erbB3 (via interactions with another RTK, particu-
larly erbB2) also gives rise to chemoresistance in cancer
treatment. Docetaxel-based chemotherapy has been estab-
lished as the standard of care for mCRPC. However, only
half of the patients benefit from docetaxel. Of these, the
majority will become resistance and eventually die of
mCRPC [67,73]. Mechanistic studies suggest that activation
of erbB3 signaling plays a vital role in the progression of
mCRPC into docetaxel resistance [17]. Increased secretion
of HRG has been found in a subset of ovarian cancers,
and thereby stimulates ovarian cancer cell proliferation via
erbB3/HRG autocrine loop [19]. Recent studies suggest that
erbB3 signaling also contributes to chemoresistance in
ovarian cancer, as the chemotherapeutic drug doxorubicin
upregulates erbB3 ligands to activate the erbB3/PI-3 K/Akt
signaling in ovarian cancer cells [74]. Thus, targeting of
erbB3 may significantly sensitize ovarian tumors to the kill-
ing effects of platinum-based or other chemotherapy regi-
mens [18]. Our early studies showed that co-expression of
erbB2 and erbB3 in human breast cancer cell lines induced
Figure 1 ErbB3 interacts with erbB2 to activate signaling
pathways leading to multi-drug resistance in breast cancer.
Hetero-dimerization of erbB2 and erbB3 is able to induce activation
of multiple downstream signaling pathways. In both luminal B and
erbB2+ subtypes of human breast cancer, erbB2/erbB3 association
may recruit IGF-1R to form a trimeric complex activating PI-3 K/Akt
signaling and Src kinase and resulting in trastuzumab resistance. In
erbB2+ breast cancer, interaction between erbB2 and erbB3 upregulates
Survivin via a PI-3 K/Akt-dependent mechanism, and thereby confers
paclitaxel resistance. In luminal B breast cancer, the erbB2/erbB3
hetero-dimers modulate ERα phosphorylation (activation) mainly
through MEK/MAPK and/or PI-3 K/Akt signaling pathways, and
subsequently alter tamoxifen sensitivity. These data support the
hypothesis that targeting of erbB3 will significantly enhance the
efficacy of those commonly used therapeutics in the treatment of
erbB2+ breast cancer.
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an increased resistance to multiple chemotherapeutic agents,
such as paclitaxel, doxorubicin, 5-fluorouracil, etoposide, and
camptothecin [60].
In the last several years, our laboratory has focused on
studying the unique biology of erbB3 receptor in the de-
velopment of erbB2 aberrant breast cancer. We have pub-
lished a series of articles [31,32,75,76] indicating that
estrogenic promotion of erbB2 kinase activity in mam-
mary tumor cells requires erbB3, and the activation of
erbB3 signaling plays an essential role in erbB2-mediated
therapeutic resistance to tamoxifen, trastuzumab, and pac-
litaxel (Figure 1). We showed that specific knockdown of
erbB3 by a siRNA abrogated erbB2-mediated tamoxifen re-
sistance in breast cancer cells via enhanced apoptosis [31].
The molecular mechanism responsible for the increased
sensitivity to tamoxifen upon erbB3 downregulation was
due to decreased levels of phosphorylated Akt (P-Akt), al-
tering the phosphorylation status of ERα. It is well-known
that the PI-3 K/Akt signaling is associated with tamoxifen
resistance and MCF-7 cells expressing a constitutively ac-
tive Akt proliferate under reduced estrogen conditions
and are resistant to tamoxifen-mediated growth inhibition
[77-79]. Both erbB3 and IGF-1R-initiated signaling path-
ways contribute to trastuzumab resistance [80-82]. None-
theless, the relationship between erbB3 and IGF-IR in
trastuzumab resistance remains unclear. We recently dis-
covered that the erbB2 receptor simultaneously interacted
with erbB3 and IGF-1R to form a trimeric complex in
trastuzumab-resistant breast cancer cells, and that it was
the hetero-trimerization of erbB2/erbB3/IGF-1R, not the
hetero-dimer of erbB2/erbB3 or IGF-1R/erbB2, that played
a critical role in the breast cancer cells resistant to trastuzu-
mab [75]. Further studies showed that specific knockdown
of either erbB3 or IGF-1R was able to reverse trastuzumab
resistance, and significantly enhanced trastuzumab-mediated
growth inhibitory effects on the otherwise resistant cells. For
the downstream signaling, specific knockdown of erbB3 de-
creased the levels of both P-Akt and P-Src, whereas IGF-1R
knockdown only gave rise to reduction of P-Src [75]. Our
data suggest that erbB3 and IGF-1R initiate different signal-
ing pathways contributing to trastuzumab resistance - erbB3
activates both PI-3 K/Akt signaling and Src kinase,
whereas IGF-1R mainly elicits Src activation. In identifying
the key downstream mediators through which erbB3 con-
tributes to chemoresistance, we found that elevated ex-
pression of erbB3 conferred paclitaxel resistance in erbB2
+ breast cancer cells via PI-3 K/Akt-dependent upregula-
tion of Survivin, a critical inhibitor of apoptosis [76].
Survivin is selectively expressed in a variety of human ma-
lignancies and its expression positively correlates with
poor prognosis, tumor recurrence and therapeutic re-
sistance [83]. Thus, novel strategies targeting Survivin,
such as antisense oligonucleotide and pharmacologicalinhibitors may significantly enhance chemotherapeutic ef-
ficacy and are currently under clinical trials for cancer
treatment [83-85]. Nonetheless, the precise mechanism by
which erbB3 signaling specifically upregulates Survivin,
but not the functionally related molecules Mcl-1 and Bcl-
xL in erbB2+ breast cancer cells [76] remains unknown.
Strategies to inhibit erbB3 signaling for cancer therapy
It is clear that there is overwhelming evidence to support
the importance of erbB3 signaling in cancer progression,
particularly in therapeutic resistance followed by tumor re-
currence [14]. Concomitant inhibition of erbB3 is thought
to be required to overcome the resistance and effectively
treat cancer patients. Indeed, advances have been made in
developing erbB3-targeted therapy [86], and several anti-
erbB3 monoclonal Abs exhibit efficacy in vivo and
show promise as novel cancer therapeutics [87,88].
Both erbB3-specific inhibitors and pan-erbB inhibitors
Figure 2 Current and novel therapeutic strategies targeting of
erbB2 and/or erbB3 receptors for cancer therapy. Several
erbB2-targeted therapies (trastuzumab, pertuzumab, T-DM1, and
lapatinib) have being used in clinic, whereas no erbB3-targeted therapy
has been approved for cancer treatment. Blocking Abs, such as
MM-121, MM-111, AMG 888/U3-1287, and MP-RM-1/EV20, are the only
agents being tested in early clinical and/or preclinical investigations.
Our recent data show that entinostat, a class I HDAC inhibitor
selectively downregulates erbB2/erbB3 via induction of specific miRNAs,
miR-125a, miR-125b, and miR-205 in erbB2+ breast cancer cells. Further
characterization demonstrates that these “sister” miRNAs (share common
targets) act in concert to inhibit erbB2/erbB3 protein translation. Thus,
the novel strategy, like cooperative miRNA targeting of erbB2/erbB3 may
represent a new approach for cancer therapy.
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bers have been developed, and a number of them are in
early clinical development. A computational model was
used to explore the optimal way to therapeutically inhibit
the erbB3 signaling-induced by combinatorial ligands [23].
This study revealed a dominant role of erbB3 in Akt activa-
tion and suggested that targeting this key node of the erbB
signaling network might result in therapeutic benefit to
cancer patients. However, a principal challenge to target
erbB3 is that, unlike other erbB family members, the erbB3
receptor lacks or possesses much lower intrinsic kinase
activity [10,11], suggesting that its function cannot be
inhibited by a small molecule inhibitor (Figure 2). Thus,
targeting of erbB3 with a blocking Ab is the only strategy
currently under preclinical investigation [22,23] and clin-
ical evaluation in patients with advanced solid tumors
(http://www.clinicaltrials.gov). Recent studies have identi-
fied bispecific Abs dual-targeting of EGFR/erbB3 [21] or
erbB2/erbB3 [25], that exert potent antitumor activities in
laboratory research and are now in clinical testing [86]. In
addition, the erbB3 inhibitors based on a novel biologic
scaffold termed a surrobody have been developed and
show inhibitory effects on tumor cell proliferation in vitro
and in vivo [89].
MM-121 is a fully humanized anti-erbB3 monoclonal
IgG2 Ab. It inhibits ligand-induced dimerization of erbB3
and erbB2 and subsequently inactivates the downstream
signaling. MM-121 has been shown to exert antitumor ac-
tivity in preclinical models of various human cancers
[22,23]. At present, clinical trials are recruiting patients
with advanced solid tumors for phase I or II studies of
MM-121 in combination with chemotherapy or other
erbB inhibitors. However, whether MM-121 has the thera-
peutic potential to overcome resistance to trastuzumab or
chemotherapy, like paclitaxel in erbB2+ breast cancer cells
remains unclear. We have recently tested the hypothesis
that MM-121 abrogates erbB3 signaling-mediated resist-
ance to trastuzumab and paclitaxel in erbB2+ breast
cancer cells via inactivation of erbB3 and its downstream
PI-3 K/Akt signaling. Our data showed that MM-121 re-
duced the expression of Survivin, overcame paclitaxel re-
sistance, and significantly enhanced paclitaxel-induced
apoptosis in the otherwise resistant breast cancer cell lines
[90]. We also found that treatment of erbB2+ breast can-
cer cell lines refractory to trastuzumab with MM-121
resulted in a dramatic inhibition of PI-3 K/Akt signal-
ing. MM-121 significantly enhanced trastuzumab-induced
growth inhibition in erbB2+ breast cancer cell lines, and
was able to overcome trastuzumab resistance [91]. While
MM-121 in combination with trastuzumab mainly inhib-
ited proliferation via cell cycle G1 arrest in vitro, their
combinatorial in vivo antitumor activity could be attrib-
uted to induction of both growth inhibition and apoptosis
[91]. Our data strongly support the development of clinicalstudies to evaluate the efficacy of MM-121 in combination
with trastuzumab or paclitaxel in therapeutically resistant
erbB2+ breast cancer patients. MM-111 is a bispecific anti-
body, dual-targeting erbB2/erbB3 and inhibiting the down-
stream signaling, like PI-3 K/Akt pathway [25]. The safety
and clinical activity of MM-111 is now being tested in sev-
eral phase I clinical trials. Another erbB3-targeted drug, U3-
1287/AMG-888, is the first fully humanized anti-erbB3
monoclonal Ab and currently under clinical studies in pa-
tients with advanced solid tumors as well. This Ab inhibits
proximal and distal erbB signaling and induces rapid in-
ternalization of erbB3 [92]. AMG-888 shows growth inhibi-
tory effects on multiple cancer cell lines (breast, lung,
colorectal) that are resistant to other erbB inhibitors [92]. It
also significantly decreases colony formation in pancreatic
cancer cells and tumor growth in pancreatic cancer,
NSCLC, and colorectal cancer xenograft models [17]. Re-
cently, a new anti-erbB3 Ab (MP-RM-1) and its humanized
version (named EV20) both have been shown to exhibit an-
titumor activity against various cancer types in vitro and
in vivo [93,94]. Because this Ab has the ability to inhibit
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erbB3 [93,94], we speculate that EV20 may have a much
broader effect on blocking erbB3 signaling than those Abs
(like MM-121) which only prevent ligand-induced activa-
tion of erbB3, and thus exert more potent activity to over-
come drug resistance in cancer therapy.
Most erbB3-targeted therapies under development
aim to inhibit erbB3 signaling by targeting the extracel-
lular domain of the receptor. Novel approaches targeting
of erbB3 have been proposed. One of these, EZN-3920
(Enzon Pharmaceuticals, Inc., Piscataway, NJ) is a high-
affinity, locked nucleic acid (LNA) antisense oligonucleo-
tide. It specifically downregulates erbB3 and demonstrates
significant antitumor activity in mouse xenograft models
of breast and lung cancer cell lines [95]. Clinical testing of
EZN-3920’s activity in cancer patients is not initiated yet.
We reported that the specific class I HDAC inhibitor enti-
nostat (also known as MS-275 or SNDX-275, Syndax
Pharmaceuticals, Inc., Waltham, MA) selectively downreg-
ulated erbB2/erbB3 receptors and induced apoptosis in
erbB2+ breast cancer cells [96]. It appeared that entinostat
reduced erbB2/erbB3 through a transcription-independent
mechanism, as it had no effect on mRNA levels of erbB2/
erbB3. Further characterization revealed that entinostat
upregulated three erbB2/erbB3-targeting miRNAs (miR-
125a, miR-125b, and miR-205) which acted in concert
to inhibit erbB2/erbB3 translation [97]. Thus, miRNA-
mediated epigenetic regulation may represent a new
mechanism inactivating erbB2/erbB3. We hypothesize that
targeting of erbB3 by “sister” miRNAs [98] via functional
cooperation may be developed as a novel therapeutic stra-
tegy against erbB3 (Figure 2). Detailed analysis is war-
ranted to test this innovative idea in vitro and in vivo.
Conclusions and future directions
Research on erbB receptors has long been focused on
dysregulation of tyrosine kinase activity of EGFR and
erbB2 in human cancers. Recently, the role of erbB3 as
an obligate partner and in primary and acquired resist-
ance to cancer therapeutics has attracted considerable
attention. Increased awareness of erbB3 function in can-
cer progression, particularly tumor recurrence following
drug resistance has several implications for future direc-
tions of investigation. ErbB3 may be considered as a
valuable biomarker to predict the efficacy of EGFR- and/
or erbB2-targeted therapy in the treatment of NSCLC and
erbB2+ breast cancer, respectively. Therapeutic targeting
of erbB3 has been shown to be an effective way to conquer
drug resistance and significantly enhance the antitumor
activity of hormonal therapy, targeted therapy, chemother-
apy, and radiotherapy. Although numerous studies have
dramatically improved our understanding of the biologic
features of erbB3 receptor in cancer biology, and advances
have been achieved in developing Abs against erbB3 withtherapeutic potential, a number of critical questions still
exist. First, activation of erbB3 signaling not only confers
drug resistance in cancer treatment, but also promotes
tumor metastasis [99-103]. The critical downstream media-
tors that are responsible for erbB3 signaling-induced cancer
metastasis remain unclear. We found that PI-3 K/Akt-
dependent upregulation of Survivin played a vital role in
erbB3-mediated paclitaxel resistance in erbB2+ breast can-
cer cells, and specific knockdown of Survivin abrogated the
resistance [76]. However, it is unknown whether the in-
creased Survivin may lead to resistance to all therapeutic
agents. Identifying other mediators of erbB3 signaling may
provide additional opportunities to develop novel strategies
revoking drug resistance and tumor metastasis. Second,
when considered individually, both erbB2 and erbB3 have
defects in that erbB2 has no known ligand and erbB3 has
impaired kinase activity. These two receptors rely on each
other to elicit the most biologically active and potent activa-
tion of PI-3 K/Akt signaling [58,59]. Nonetheless, the mo-
lecular basis through which tumor cells often co-express
erbB2 and erbB3 remains elusive. It is not clear whether
same mechanisms are utilized to simultaneously upregulate
both erbB2 and erbB3, or whether tumor cells first overex-
press one receptor which subsequently enhances expression
of the other receptor. Third, targeting of erbB3 with a
blocking Ab is active in both preclinical and clinical studies.
However, tumor cells may eventually develop resistance to
the anti-erbB3 Abs, since the Abs like EGFR/erbB2-
targeted therapies just inhibit signaling without altering
expression of the erbB receptors. We believe that new
strategies/agents that aim to reduce erbB3 protein levels,
such as the antisense oligonucleotide EZN-3920 [95],
the HDAC inhibitor entinostat [96], and the cooperative
“sister” miRNAs [97,98] may hold special antitumor activity
as the tumor cells won’t have opportunities to develop re-
sistance. Finally, HRG is vital to induce activation of erbB3
signaling. Aberrant production and/or maturation of HRG
will affect tumor cell survival and proliferation. Thus,
studies on dysregulation of HRG in cancers may improve
our understanding of the ligand’s biological function in
erbB3-mediated tumor initiation and progression, and
facilitate the development of novel strategy for cancer
therapy. It is conceivable to hypothesize that novel ap-
proaches against HRG, such as neutralization Abs, may exert
similar anti-tumor efficacy as therapeutic targeting of erbB3.Abbreviations
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